Cytological profiling: providing more haystacks for chemists' needles by Lorang, Janet & King, Randall Wharton
 
Cytological profiling: providing more haystacks for chemists'
needles
 
 
(Article begins on next page)
The Harvard community has made this article openly available.
Please share how this access benefits you. Your story matters.
Citation Lorang, Janet and Randall W. King. 2005. Cytological profiling:
providing more haystacks for chemists' needles. Genome Biology
6(8): 228.
Published Version doi:10.1186/gb-2005-6-8-228
Accessed February 19, 2015 4:05:06 AM EST
Citable Link http://nrs.harvard.edu/urn-3:HUL.InstRepos:4743815
Terms of Use This article was downloaded from Harvard University's DASH
repository, and is made available under the terms and conditions
applicable to Other Posted Material, as set forth at
http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-
of-use#LAAGenome Biology 2005, 6:228
c
o
m
m
e
n
t
r
e
v
i
e
w
s
r
e
p
o
r
t
s
d
e
p
o
s
i
t
e
d
 
r
e
s
e
a
r
c
h
i
n
t
e
r
a
c
t
i
o
n
s
i
n
f
o
r
m
a
t
i
o
n
r
e
f
e
r
e
e
d
 
r
e
s
e
a
r
c
h
Minireview
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Abstract
Conventional high-throughput ‘chemical genetic’ screening seeks to identify small-molecule
inhibitors of a specific protein or pathway. A recent study describes how unbiased screening of
cellular morphology, followed by affinity purification to identify targets of compounds with
interesting effects, can lead to the identification of novel inhibitors.
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Scientists in the pharmaceutical industry are in constant
search of new drugs that can activate or inhibit their target
molecule of interest. Combinatorial chemistry has allowed
the synthesis of huge numbers of new compounds by com-
bining sets of building blocks, and researchers are busily
sorting through this haystack of drugs for the perfect needle
- a drug specific for the intended target. The usual approach
to this search is high-throughput screening of a large library
of compounds (500,000 to 1,000,000 compounds is typical)
in an assay for a single, specific effect, such as inhibition of
an enzyme. Although this strategy allows large numbers of
molecules to be screened, it measures only a limited range of
biological effects. The vast majority of compounds screened
will fail to show the desired effect and will be discarded as
useless. Thus, molecules that may have interesting and
useful characteristics will be missed if they do not have the
specific effect that is being measured in the screen.
Screening strategies that measure the effects of compounds
on biological pathways, rather than single proteins, cover a
broader subset of biological space. As a result, a larger
number of active compounds may be identified from a given
chemical library. Several enzymes or proteins could be tar-
geted in such an assay. For example, targeting of a receptor,
adaptor protein, or transcription factor in one pathway could
all be detected in a single assay for activation of a reporter
construct that responds to the transcription factor. Porter
and colleagues [1] performed such a screen for agonists of
the pathway downstream of the extracellular signaling mole-
cule Hedgehog, by looking for small molecules that caused
up-regulation of a Hedgehog-responsive promoter. The
agonist identified in this screen acts by binding Smoothened,
a Hedgehog activator protein related to G-protein-coupled
receptors, but agonists of any of the components of this sig-
naling pathway could have been identified in the screen [1]. 
Cytological screening for active compounds
A recent paper by Adams, Shokat, and colleagues [2] goes a
step beyond screening that uses a specific pathway to
broaden further the biological spectrum of activities that can
be detected in a single screen. In their study [2], a relatively
small number (107) of compounds that are structurally
similar to known kinase inhibitors were selected for screen-
ing. Rather than screening each of these molecules for inhi-
bition of a specific enzyme or pathway, or for a specific
phenotype produced, the authors instead searched for small
molecules that perturbed any measurable aspect of cell mor-
phology using a cytological profiling approach. Five cell
types (four cancer cell lines plus endothelial cells) were
treated with each compound at a range of doses, and the
effects on cell morphology were analyzed using an auto-
mated imaging and analysis system (CytoMetrix
TM by Cytoki-
netics, San Francisco, USA). Cells were stained with reagentsthat detected DNA, the Golgi apparatus, and microtubules
(see Figure 1). The Cytometrix system was then used to
measure a large number of different parameters, including
the morphology of the cell and organelles (nuclei, micro-
tubules, and Golgi), staining intensity, and localization of
organelles in each cell type for each treatment condition [2]. 
The large number of images collected and measurements
made in this system yielded a large volume of data, which
was condensed using a method called principle component
analysis. This statistical-analysis method converts the many
variables measured into a smaller number of ‘principle com-
ponents’, which represent the majority of the variability in
the dataset with a small number of parameters. The princi-
ple component analysis grouped the active compounds into
three ‘phenotypes’, two of which were characteristic of com-
pounds that stabilized microtubules or inhibited protein
kinases. The final phenotype was produced by only one com-
pound, called hydroxy-PP, and was distinct from that of
compounds with known mechanisms of action. Although
structurally related to known kinase inhibitors, hydroxy-PP
caused a phenotype distinct from other kinase inhibitors,
suggesting that hydroxy-PP is likely to act through a distinct
mechanism [2].
To determine how hydroxy-PP induced this unique pheno-
type, an affinity-purification approach was pursued to iden-
tify the biochemical target of the compound. Affinity
chromatography using small molecules can often be very
challenging if a compound binds its target weakly or if the
compound binds many proteins nonspecifically. To circum-
vent these problems, the authors [2] synthesized a pair of
structurally related compounds that could be attached to a
solid-phase matrix. One compound retained activity,
whereas a highly structurally related compound (differing
only by the absence of a hydroxy group) was used as an inac-
tive control. Cell lysates were applied to both columns, and
many different wash conditions were tested until proteins
were retained specifically on the matrix containing the active
compound and not the other matrix. This approach yielded
only a few potential binding proteins, one of which was iden-
tified as carbonyl reductase 1 (CBR1), an NADPH-dependent
oxidoreductase that has been implicated in detoxification of
foreign compounds and the metabolism of cellular messen-
gers containing ketone groups, such as prostaglandin E.
To confirm that hydroxy-PP is indeed an inhibitor of CBR1,
the authors [2] showed that the compound was capable of
inhibiting CBR1 in a biochemical assay in vitro, with a con-
centration that gives 50% inhibition (IC50) of 788 nM. The
compound was also found to be a potent inhibitor of cellular
kinases such as the c-Src family member Fyn (IC50 = 5 nM),
however, limiting the usefulness of hydroxy-PP for further
studies. Structure-based design was therefore used to design
a more specific inhibitor, termed hydroxy-PP-Me, which was
shown to lack kinase-inhibitory activity. This inhibitor was
then used to characterize more closely the biological role of
CBR1 and to evaluate the potential therapeutic utility of
the inhibitor. 
Why would an inhibitor of CBR1 be medically useful? The oxi-
doreductase activity of CBR1 is thought to be responsible for
the cardiotoxicity of anthracycline anti-cancer drugs such as
daunorubicin. CBR1 metabolizes daunorubicin into daunoru-
bicinol, which lacks anti-cancer activity and has adverse
affects on the heart. A specific inhibitor of CBR1 could be
useful in cancer therapy to maintain daunorubicin in its active
form and to prevent the toxicity associated with treatment
with anthracycline-type drugs. Tanaka et al. found [2] that
treatment of cancer cells with hydroxy-PP-Me was able to
strengthen the cell-killing effect of daunorubicin. No enhance-
ment of cell killing by daunorubicin was observed when a
related molecule PP-L, which does not inhibit CBR1, was used.
This suggests that CBR1 inhibition enhances killing of cancer
cells by blocking metabolism of daunorubicin. Thus, not
only  may CBR1 inhibition have the potential to block
daunorubicin-induced cardiotoxicity, it may also potentiate
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Figure 1
The principle of cytological profiling. Cells are treated with test
compounds at varying concentrations and then stained with reagents that
detect various cellular proteins or organelles. In this example, cells are
treated with reagents that detect cellular DNA, the Golgi apparatus, or
microtubules. Compound 1 shows a profile characteristic of a
microtubule stabilizer, which leads to longer microtubules but dispersed
DNA and Golgi apparatus as a result of the mitotic arrest that is a
secondary consequence of microtubule stabilization. Compound 2 has
more subtle effects, inducing changes in nuclear size and shape, with little
effect on microtubules and only a small shift in the position of the Golgi.
In an actual experiment (such as in [2]), cytological changes are measured
at a variety of different drug concentrations, and a variety of
measurements are made on each image. This complex dataset is then
reduced using various statistical approaches to identify the key
parameters that change as a function of drug concentration. 
DNA
Golgi
Microtubules
Compound 1 Compound 2 Untreatedcancer-cell killing by maintaining daunorubicin in its active
form. Further investigation of the compound’s effects in cells
revealed that inhibition of CBR1 by hydroxy-PP-Me protects
cells against the apoptosis induced by serum withdrawal [2].
This result was confirmed by knocking down the levels of
CBR1 using RNA interference, thus identifying a previously
unknown role for CBR1 in apoptosis.
The classical method of high-throughput chemical screening
covers a broad subset of chemical space but a very narrow
subset of biological space. The work of Shokat and col-
leagues [2] demonstrates that the converse strategy - screen-
ing a small chemical library using an assay that measures a
large number of potential biological outcomes - can also lead
to the identification of novel and specific inhibitors. As
described earlier, these researchers [2] also found that com-
pounds with related mechanisms of action, such as kinase
inhibition, had similar profiles or phenotypes in the screen.
This suggests that it might be possible to use cytological pro-
filing to generate ‘fingerprints’ characterizing the potential
mechanism of action of novel compounds. 
Multidimensional profiling 
A paper by Altshuler, Mitchison, and colleagues [3] demon-
strated that it is indeed possible to generate specific finger-
prints of many biologically active compounds through
immunofluorescent measurement of the abundance and local-
ization of specific protein markers in cells. In this study [3],
HeLa cells were treated with 100 different compounds, all with
a known biological target, at a wide range of concentrations.
Cells were then fixed and stained with antibodies or dyes that
reported on 11 distinct proteins or cellular processes. Auto-
mated microscopy was used to collect images of the cells, and
computer algorithms were then used to analyze the images
and generate cytological dose-response profiles of each drug.
These profiles describe both the phenotypic changes induced
by each drug and the dose at which these changes occur. 
Of the 100 compounds tested in this study [3], 61 showed
measurable effects, indicating that a broad range of biologi-
cal effects can be detected with a limited number of markers.
The fact that 39 compounds appeared to have no measurable
effect suggests, however, that additional markers beyond the
11 used in this study will be required in order to increase
further the sensitivity of the approach. This raises the inter-
esting question of how many markers would be required to
detect a perturbation of any biological pathway. To minimize
the total number of markers required, it will also be impor-
tant to identify markers specific to the effects of only one
biological pathway. Further optimizing the set of markers
will also require a better understanding of how different bio-
logical pathways interact with one another. 
Of the drugs that did show a response in the Altshuler study
[3], those with common targets and mechanisms generally
showed similar profiles. Drugs with similar chemical struc-
tures but distinct mechanisms of actions showed dissimilar
profiles. Thus, this approach is capable of grouping drugs
with similar mechanisms of action together, suggesting that
it may be useful for predicting the potential mechanisms of
action of new compounds and identifying the targets of com-
pounds identified in phenotypic or pathway-based screens.
Cellular profiling may also provide useful insights into the
potential toxicities of compounds of interest identified in
conventional single-target high-throughput screens. In this
case, markers that report on activation of cell stress path-
ways may be especially valuable. 
A variety of other profiling approaches have been developed
for characterizing the activity and specificity of small mole-
cules at the cellular, protein, or mRNA level [4-10]. How
does cytological profiling complement these approaches?
First, it provides details of the intracellular localization of
marker proteins, making it a sensitive indicator of the many
pathways that regulate protein localization. Second, cellular
organelles such as the Golgi apparatus or the nucleus, which
depend on the activity of many pathways for proper organi-
zation and function, may provide very sensitive readouts of
functional perturbations. This property may make cytologi-
cal profiling useful for detecting toxic or off-target effects of
molecules of interest. Finally, imaging-based approaches
provide information on a cell-by-cell basis; they do not
average effects over entire populations of cells as is the case
for RNA-based or protein-based (proteomic) approaches.
This may enable more sensitive detection of effects in sub-
populations of cells, and it may enable effects to be detected
at lower doses of compounds. 
Most small-molecule screening has been performed with large
chemical libraries tested against specific biological pathways
or targets. This ‘biology-centric’ view of screening serves an
important purpose: to identify small-molecule probes or com-
pounds of interest to biologists or those working to cure a spe-
cific disease. This approach leaves much to be desired,
however, if you are a chemist who has recently designed a
novel chemical library and you want to understand how each
molecule in your library might perturb biological function. In
this case, ‘chemistry-centric’ approaches are needed, which
can identify the compounds in the library that have any bio-
logical activity at all. Cytological profiling, which takes an
unbiased approach to discovery of biological activity, provides
an excellent starting point for discovering novel biological
activities or therapeutic potential in a collection of novel mole-
cules. The results of such profiling studies may be especially
useful in helping to guide which areas of chemistry space need
to be more fully developed and explored [11].
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